UnknownNot Applicable

Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP

50 participantsStarted 2023-07

Plain-language summary

1. Screening for MDR-hvKP causing VAP in patients admitted to chest ICU in Assiut University Hospital. 2. In vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against clinical MDR-hvKP isolates by checkerboard and time killing assay. 3. In vivo evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin using MDR-hvKP septic rat model.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Fever (\>38 oC) with no other recognized cause
✓. WBCs \< 4000/mm3 or \>12000/mm3
✓. New onset of purulent sputum.
✓. Increase in respiratory secretion or increased need for suctioning.
✓. New-onset or worsening cough, or dyspnea, or tachypnea worsening gas exchange.

What they're measuring

Synergistic effect of plasmid inhibitors and antimicrobial drugs against MDR-hvKP invitro.

Timeframe: 24hours

Trial details

NCT IDNCT05932355

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07

Contact for this trial

Shereen Elnokrashy Mohamed, Teaching Assistant

+201093156381 shereenelnokrashy96@gmail.com

View on ClinicalTrials.gov More Synergy Between Plasmid Inhibitors and Combined Antibiotics trials